logo
My cultural awakening: A Timothée Chalamet drama made me leave my partner – and check him into rehab

My cultural awakening: A Timothée Chalamet drama made me leave my partner – and check him into rehab

Yahooa day ago

Two summers ago, I met a man on a dating app who would become my boyfriend. The red flags were there from the start, but I ignored them all. When I stayed at his, he didn't have a towel to offer me, and he never changed his sheets. It became obvious that he didn't know how to look after himself. Even though, in reality, he could survive without me (similar to how a teenage boy would survive on his own, eating burgers in bed), I felt like, if I wasn't there to buy groceries, cook and clean, he might die. He would disappear for days, on a drink- or drugs-fuelled bender, and I'd assume he'd overdosed in a basement somewhere. I lived in fear that something terrible would happen to him. I became his boyfriend and his caregiver.
This was a familiar role for me: I'd done it in all my previous relationships. I needed to be needed. If the person I was dating didn't need me, then what value did I have? I found safety in taking care of someone. This started as a family dynamic: as the eldest child, I had to look out for my younger brothers, and learned to overlook my own needs. Then, when I was 14, my girlfriend died in a drug-related car accident. My therapist helped me to see the connection; that because I couldn't save her, I sought romantic relationships with men or women I thought I could save instead.
I hadn't seen how much I was damaging myself by trying to help him. And that I never would never be able to
One evening, after being recommended it by Netflix, I began watching Beautiful Boy, a film about the breakdown of a father's relationship with his son, who is an addict. It was about halfway through that I decided to leave my relationship. When Steve Carell's character (David) hangs up on Timothée Chalamet (Nic), saying, 'I wish I could help you, but I can't do that,' I knew I couldn't either. I admired the strength it took to end the cycle of trying (and failing) to save his son.
Even though he was my boyfriend and three years older, I related to the father-son dynamic in Beautiful Boy. I felt responsible for him, and he would tell me that he would die without me, threatening to take his own life. Until then, I hadn't seen how much I was damaging myself by trying to help him. And that I would never be able to, not really. He had to learn how to take care of himself. As David says: 'I don't think you can save people.'
Despite deciding to end the relationship in September 2023, I didn't take action until October, when I cheated on him. I felt I had to do something irreparable that would make it impossible for us to stay together. I told him what I'd done over the phone, then I called his mum to tell her about his drug problem. I don't think she knew: she lived in another country and he hid it from her. Finally, I called a psychiatric facility and did all of the admin to make sure that he would be taken care of, and then never spoke to him again. The guilt I felt was overpowered by the feeling that this was something I had to do.
That was my last codependent relationship. I have a new boyfriend, who tells me that my company alone is enough. I'm the most peaceful I've ever been, but sometimes the voice that says I'm only lovable if I'm useful comes back. If I try to cook for my boyfriend when I'm tired and he tells me I don't have to, I can spiral. But slowly, with help, I'm building a sense of self that doesn't rely on being of service. Beautiful Boy helped me see that I don't need to take care of someone else to have value.
Action on Addiction is available on 0300 330 0659.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Which Class of ER Degrader Is Better?
Which Class of ER Degrader Is Better?

Medscape

time7 minutes ago

  • Medscape

Which Class of ER Degrader Is Better?

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), outshone the commonly used selective estrogen receptor degrader (SERD) fulvestrant in a phase 3 trial of second-line treatment for a subset of patients with breast cancer. The VERITAC-2 trial included patients with ER-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), locally advanced or metastatic disease who had failed prior treatment with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and endocrine therapy, and no exposure to chemotherapy in the advanced setting. Only a subset of the study cohort, those with estrogen receptor 1-mutant disease, experienced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when treated with vepdegestrant compared with patients treated with fulvestrant. 'These results support vepdegestrant as a potential monotherapy treatment option for patients with previously treated ESR1 -mutant ER+/HER2- advanced breast cancer,' said lead author Erika P. Hamilton, MD, a medical oncologist and director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, Nashville, Tennessee, during a press conference for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings were simultaneously published in the New England Journal of Medicine . Vepdegestrant is not approved by the US Food and Drug Administration, but received fast-track status in February 2024 as monotherapy for this patient population. It is the first and only PROTAC ER degrader to be evaluated in a phase 3 clinical trial in breast cancer. PROTACs represent a novel class of therapeutic agents that harness the proteasome to selectively degrade target proteins. 'There's no established consensus for patients getting treatment in the second-line setting after progression on endocrine therapy and a CDK 4/6 inhibitor,' explained Hamilton. 'One of the mainstays of our treatment really has been fulvestrant, which clearly has some challenges. First, it's administered intramuscularly, and second, in a post-CDK 4/6 landscape, we know that progression-free survival is very short — on the order of less than 2 months.' Besides fulvestrant, the oral SERD elacestrant was FDA-approved in January 2023, and other oral SERDs are in development, she noted. Trial Design The new trial included 624 patients with advanced ER+/HER2- disease that had progressed following one or two lines of endocrine therapy and a CDK 4/6 inhibitor. 'They could not have received fulvestrant already or chemotherapy, and patients had to have benefited from their previous line of endocrine therapy for at least 6 months to enter the study,' Hamilton noted. Study participants were also stratified by the presence or absence of visceral disease, as well as the presence of an ESR1 mutation (n = 270). Such mutations are a common cause of acquired resistance found in approximately 40% of patients in the second-line setting, according to a press release from the drug developer. Patients were randomly assigned 1:1 to 28-day treatment cycles of either 200 mg oral vepdegestrant once daily, or 500 mg intramuscular fulvestrant on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle. The primary endpoint was PFS by blinded, independent central review, first in patients with ESR1 mutations and then in the entire cohort. Key secondary endpoints were overall survival, objective response rate, and clinical benefit rate, which was defined as the rate of confirmed clinical or partial response at any time, or stable disease, nonclinical response, or nonprogressive disease for at least 24 weeks. Vepdegestrant vs Fulvestrant The study met its key primary endpoint, showing a median PFS of 5.0 months with vepdegestrant compared with 2.1 months with fulvestrant (hazard ratio [HR] 0.57; P < .001) in the 270 patients with ESR1 mutations. At 6 months, twice as many patients in the vepdegestrant arm remained progression-free compared with those in the fulvestrant arm (45.2% vs 22.7%). However, this primary endpoint was not significantly different between groups when calculated for the entire patient population (HR, 0.83; P = .07). For the key secondary endpoints, among patients with ESR1 mutations, the clinical benefit rate was more than double in patients receiving vepdegestrant (42.1% vs 20.2%). Similarly, the objective response rate was more than four times higher (18.6% vs 4%) Commenting in a press release, ASCO breast cancer expert Jane Lowe Meisel, MD, said that although the trial found that vepdegestrant worked better than fulvestrant in patients with ESR1 mutations, 'on average, patients did not have prolonged responses on either agent, highlighting the need for combination therapies and continued development in this space.' Meisel is co-director of Breast Medical Oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta, Georgia. 'Overall survival was very immature at the time of this analysis, with only 20% of the anticipated events occurring,' added lead investigator Hamilton. Treatment-emergent adverse events (TEAEs) led to discontinuation in 3% of patients taking vepdegestrant and 1% of patients taking fulvestrant. TEAEs leading to dose reductions occurred in 2% of the vepdegestrant group and none in the fulvestrant group. The three most common AEs of any grade were fatigue (27% in vepdegestrant group, 16% fulvestrant group) and increased aspartate aminotransferase and alanine aminotransferase levels of any grade (14% vepdegestrant group, 10% fulvestrant group). Oral SERDS vs Vepdegestrant Side Effects Compared to oral SERDs, vepdegestrant has a favorable side effect profile, Hamilton said. 'Oral SERDs have prominent GI side effects as their most frequent side effect.' But, across all grades, rates of both vomiting and diarrhea were only 6% with vepdegestrant. GI side effects tend to be more common, 'in the 30% or 40% range with oral SERDs,' she told Medscape Medical News . Study discussant William John Gradishar, MD, emphasized the importance of reducing side effects. ' Vepdegestrant now joins a growing list of drugs that perform better than current standard of care monotherapy' in the ESR1 -mutant population, he noted in the session. But the reality is that most of these drugs are being developed to be used in combination with targeted therapies, 'and increased toxicity can be expected with doublet therapy…Quality of life measures as experienced and reported by patients are critical, and even modest changes in symptom and functional domains should not be minimized,' said Gradishar, professor of breast oncology at Northwestern University Feinberg School of Medicine, Chicago, Illinois. 'Vepdegestrant has demonstrated compelling preclinical activity and encouraging early clinical data supporting its efficacy in degrading ER,' said Albert Grinshpun, MD, in an interview with Medscape Medical News . Grinshpun, head of the Breast Cancer Service at Shaare Zedek Medical Center and The Hebrew University, Jerusalem, Israel, said his initial takeaway from the study is that 'vepdegestrant now stands alongside other oral SERDs, such as elacestrant and imlunestrant, in demonstrating superiority over fulvestrant, specifically in the context of ESR1­ -mutant [disease].' 'Importantly, the treatment landscape for patients progressing on CDK 4/6 inhibitors is rapidly evolving, with a growing shift toward combination therapies rather than fulvestrant monotherapy,' he said. 'In my view, vepdegestrant has established itself as a promising endocrine backbone for future combination strategies. Its favorable toxicity profile makes it particularly well-suited for pairing with a range of targeted agents or even antibody-drug conjugates, including inhibitors of PIK3CA and KAT6 , in the pursuit of more effective therapeutic regimens.' The study was jointly funded by Arvinas Estrogen Receptor, Inc. and Pfizer. Hamilton disclosed consulting or advisory roles with Accutar Biotechnology (Inst), Arvinas (Inst), AstraZeneca (Inst), Circle Pharma (Inst), Daiichi Sankyo (Inst), Ellipses Pharma (Inst), Entos (Inst), Fosun Pharma (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Jefferies (Inst), Johnson & Johnson (Inst), Lilly (Inst), Medical Pharma Services (Inst), Mersana (Inst), Novartis (Inst), Olema Pharmaceuticals (Inst), Pfizer (Inst), Stemline Therapeutics (Inst), Tempus (Inst), Theratechnologies (Inst), Tubulis GmbH (Inst), Verascity Science (Inst), and Zentalis (Inst). Hamilton has also received research funding from AbbVie (Inst), Accutar Biotech (Inst), Acerta Pharma (Inst), ADC Therapeutics (Inst), Akeso Biopharma (Inst), Amgen (Inst), Aravive (Inst), ArQule (Inst), Artios (Inst), Arvinas (Inst), AstraZeneca (Inst), AtlasMedx (Inst), BeiGene (Inst), Black Diamond Therapeutics (Inst), Bliss Biopharmaceutical (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Cascadian Therapeutics (Inst), Clovis Oncology (Inst), Compugen (Inst), Context Therapeutics (Inst), Cullinan Oncology (Inst), Curis (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Dana-Farber Cancer Institute (Inst), Dantari (Inst), Deciphera (Inst), Duality Biologics (Inst), eFFECTOR Therapeutics (Inst), Eisai (Inst), Ellipses Pharma (Inst), Elucida Oncology (Inst), EMD Serono (Inst), Fochon Pharmaceuticals (Inst), Fujifilm (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), H3 Biomedicine (Inst), Harpoon (Inst), Hutchison MediPharma (Inst), Immunogen (Inst), Immunomedics (Inst), Incyte (Inst), Infinity Pharmaceuticals (Inst), Inspirna (Inst), InventisBio (Inst), Jacobio (Inst), K-Group Beta (Inst), Karyopharm Therapeutics (Inst), Kind Pharmaceuticals (Inst), Leap Therapeutics (Inst), Lilly (Inst), Loxo (Inst), Lycera (Inst), MabSpace Biosciences (Inst), Macrogenics (Inst), MedImmune (Inst), Mersana (Inst), Merus (Inst), Millennium (Inst), Molecular Templates (Inst), Myriad Genetics (Inst), Novartis (Inst), Nucana (Inst), Olema Pharmaceuticals (Inst), OncoMed (Inst), Oncothyreon (Inst), ORIC Pharmaceuticals (Inst), Orinove (Inst), Orum Therapeutics (Inst), Pfizer (Inst), PharmaMar (Inst), Pieris Pharmaceuticals (Inst), Pionyr (Inst), Plexxikon (Inst), Prelude Therapeutics (Inst), ProfoundBio (Inst), Radius Health (Inst), Regeneron (Inst), Relay Therapeutics (Inst), Repertoire Immune Medicines (Inst), Rgenix (Inst), Seagen (Inst), Sermonix Pharmaceuticals (Inst), Shattuck Labs (Inst), Silverback Therapeutics (Inst), Stem CentRx (Inst), Stemline Therapeutics (Inst), Sutro Biopharma (Inst), Syndax (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), TapImmune Inc. (Inst), Tesaro (Inst), Tolmar (Inst), Torque (Inst), Treadwell Therapeutics (Inst), Verastem (Inst), Zenith Epigenetics (Inst), and Zymeworks (Inst). Meisel disclosed consulting or advisory roles with AstraZeneca, GE Healthcare, Genentech, Novartis, Olema Oncology, Pfizer, SeaGen, Sermonix Pharmaceuticals, and Stemline, and research funding from AstraZeneca (Inst), Olema Oncology (Inst), Pfizer (Inst), Seagen (Inst), and Sermonix Pharmaceuticals (Inst). Grinshpun disclosed honoraria from GSK, Lilly, Novartis, and AstraZeneca, and travel from Roche, Pfizer, and AstraZeneca. Gradishar disclosed consulting or advisory roles with AstraZeneca , Genentech/Roche, Gilead Sciences, Merck, Novartis, Pfizer.

'Lilo & Stitch' passes 'Sinners' to become 2nd highest grossing film of 2025
'Lilo & Stitch' passes 'Sinners' to become 2nd highest grossing film of 2025

Washington Post

time16 minutes ago

  • Washington Post

'Lilo & Stitch' passes 'Sinners' to become 2nd highest grossing film of 2025

'Lilo & Stich' and 'Mission: Impossible—The Final Reckoning' dominated the box office charts again after fueling a record-breaking Memorial Day weekend . Theaters in the U.S. and Canada had several new films to offer this weekend as well, including Sony's family friendly 'Karate Kid: Legends' and the A24 horror movie 'Bring Her Back. ' According to studio estimates Sunday, it added up to a robust $145 million post-holiday weekend that's up over 115% from the same timeframe last year.

'Lilo & Stitch' passes 'Sinners' to become 2nd highest grossing film of 2025
'Lilo & Stitch' passes 'Sinners' to become 2nd highest grossing film of 2025

Associated Press

time18 minutes ago

  • Associated Press

'Lilo & Stitch' passes 'Sinners' to become 2nd highest grossing film of 2025

'Lilo & Stich' and 'Mission: Impossible—The Final Reckoning' dominated the box office charts again after fueling a record-breaking Memorial Day weekend. Theaters in the U.S. and Canada had several new films to offer this weekend as well, including Sony's family friendly 'Karate Kid: Legends' and the A24 horror movie 'Bring Her Back. ' According to studio estimates Sunday, it added up to a robust $145 million post-holiday weekend that's up over 115% from the same timeframe last year. Disney's live-action hybrid 'Lilo & Stitch' took first place again with $63 million from 4,410 locations in North America. It was enough to pass 'Sinners' to become the second-highest grossing movie of the year with $280.1 million in domestic ticket sales. Globally, it's running total is $610.8 million. 'Sinners,' meanwhile, is still going strong in its seventh weekend with another $5.2 million, bumping it to $267.1 million domestically and $350.1 million globally. The eighth 'Mission: Impossible' movie also repeated in second place, with $27.3 million from 3,861 locations. As with 'Lilo & Stitch,' that's down 57% from its opening. With $122.6 million in domestic tickets sold, it's performing in line with the two previous installments. But with a reported production budget of $400 million, profitability is a ways off. Internationally, it added $76.1 million (including $25.2 million from China where it just opened), bringing its global total to $353.8 million. Leading the newcomers was Sony's 'Karate Kid: Legends,' with an estimated $21 million from 3,809 locations. The movie brings Jackie Chan and Ralph Macchio together to train a new kid, the kung fu prodigy Li Fong ( Ben Wang ). Chan starred in a 2010 reboot of the 1984 original, while Macchio has found a new generation of fans in the series 'Cobra Kai,' which just concluded a six-season run. Reviews might have been mixed, but opening weekend audiences gave the PG-13 rated film a strong A- CinemaScore and 4.5 stars on PostTrak. It also only cost a reported $45 million to produce and has several weeks until a new family-friendly film arrives. Fourth place went 'Final Destination: Bloodlines,' which earned $10.8 million in its third weekend. The movie is the highest-grossing in the franchise, not accounting for inflation, with $229.3 million globally. The weekend's other big newcomer, 'Bring Her Back' rounded out the top five with $7.1 million from 2,449 screens. Starring Sally Hawkins as a foster mother with some disturbing plans, the film is the sophomore feature of twin filmmakers Danny and Michael Philippou, who made the 2023 horror breakout 'Talk to Me.' It earned a rare-for-horror B+ CinemaScore and is essentially the only new film in the genre until '28 Years Later' opens on June 20. A new Wes Anderson movie, 'The Phoenician Scheme,' also debuted in New York and Los Angeles this weekend, where it made $270,000. It expands nationwide next weekend. The summer box office forecast remains promising, though there's a long way to go to get to the $4 billion target (a pre-pandemic norm that only the 'Barbenheimer' summer has surpassed). The month of May is expected to close out with $973 million – up 75% from May 2024, according to data from Comscore.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store